Bristol-Myers Squibb ASCO Follow-up Conference Call - Research and Markets offers a brief of 'Bristol-Myers Squibb' Conference Call.DUBLIN, Ireland -- The Bristol-Myers Squibb (NYSE NYSE See: New York Stock Exchange :BMY BMY Bristol Myers Squibb ) Corporate Conference Call took place on 7-Jun-06 8:00am ET. Management reported that last week, the FDAs Oncologic Drug Advisory Committee unanimously recommended accelerated approval of Dasatinib for the treatment of adults with all phases of Chronic Myeloid Leukemia myeloid leukemia n. See myelogenous leukemia. with resistance or intolerance to prior therapy including Gleevec. BMY believes that the new data presented at ASCO ASCO American Society of Clinical Oncology ASCO Association of Schools and Colleges of Optometry (since 1941; Rockville, Maryland) ASCO Australian Standard Classification of Occupations ASCO Automatic Switch Company for all of the late-stage compounds are very encouraging and bodes well for future submissions regulatory authorities. More information on this Conference Call can be obtained from Research and Markets at http://www.researchandmarkets.com/transcripts/90329 This document provides a non-biased summary of the conference call detailing the key points and the full Q&A session. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion